|

Tazemetostat Clinical Trials

12 actively recruiting trials across 11 locations

Also known as: 1403254-99-8, E 7438, E-7438, E7438, EPZ 6438 +9 more

Pipeline

Phase 1: 6Phase 2: 3Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Epizyme, Inc.2
  • Weill Medical College of Cornell University1
  • University of Utah1
  • University of Alabama at Birmingham1
  • Thomas Jefferson University1

Indications

  • Cancer12
  • Refractory Follicular Lymphoma2
  • Follicular Lymphoma2
  • Hepatic Impairment1
  • Rhabdoid Tumor of the Kidney (RTK)1

Birmingham, Alabama2 trials

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

UAB Comprehensive Cancer Center

Phase 1/2
Study of Tazemetostat in Lymphoid Malignancies

University of Alabama at Birmingham

Phase 1

Mobile, Alabama1 trial

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Southern Cancer Center

Phase 3

Tucson, Arizona1 trial

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Banner University Medical Center - Tucson

Phase 2

Sacramento, California1 trial

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

University of California Davis Comprehensive Cancer Center

Phase 1

Lake Mary, Florida1 trial

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Florida Cancer Specialists & Research Institute

Phase 1

Chicago, Illinois1 trial

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Northwestern University

Phase 2

Boston, Massachusetts1 trial

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Boston Children's Hospital

Phase 1/2

New York, New York1 trial

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Weill Cornell Medicine/NewYork-Presberteryian Hospital

Phase 1

Philadelphia, Pennsylvania1 trial

Tazemetostat and Palbociclib With CPX-351for R/R AML

Thomas Jefferson University Hospital

Phase 1

Greenville, South Carolina1 trial

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Prisma Health Cancer Institute

Phase 2

Salt Lake City, Utah1 trial

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Huntsman Cancer Institute at University of Uta

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.